27.7 C
Vientiane
Thursday, June 19, 2025
spot_img
Home Blog Page 60

Digital China and INSEAD Jointly Release First AI Case

SINGAPORE, May 30, 2025 /PRNewswire/ — Guo Wei, Chairman of Digital China, shared insights on “Enterprise Management in the AI Era” at the INSEAD 2025 Asia AI Conference and  jointly released a case study with INSEAD.

Guo Wei's Speech
Guo Wei’s Speech

In his speech, Guo Wei pointed out that the interaction of Business Model, Technology Architecture, and Management Approach forms a growth flywheel that drives enterprise evolution—at the core of which lies business processes. Therefore, deeply integrating AI into the reengineering of business processes will be key to the commercialization of AI. To achieve process reengineering and meet the management goals in the AI era—full-scope awareness, rapid decision-making, and continuous iteration—enterprises must first rebuild their infrastructure. This means aligning business processes with a new data cloud integrated architecture, to fully harness the value of data assets.

When discussing AI’s impact on organizational transformation, Guo Wei said, “From an enterprise perspective, every wave of technological change brings enormous opportunities, and also significant challenges. The biggest challenge lies in building the right mindset. There’s a great deal of enthusiasm for AI in the public discourse, but its actual application in enterprise settings is still at an early stage. This gap often leads to fatigue and anxiety. We firmly believe that AI and digitalization will drive profound changes, but such transformation won’t happen overnight—it requires a gradual, step-by-step process.”

Now included in the INSEAD Case Library and soon to become part of its MBA curriculum, the case study Shaping the Future: Digital China’s Journey from Digitalization to an AI-Embedded Organization provides global learners with insights into AI-led transformation and reflects China’s growing influence on enterprise AI innovation.

This case study presents Digital China’s journey in digital transformation and its latest AI initiatives under the strategic framework of “AI-Powered Data Cloud Integration.” Reflecting global digital and AI trends, it offers valuable insights for companies pursuing similar transformations. Following earlier inclusion in the case libraries of London Business School and Harvard Business School in 2024, this latest inclusion by INSEAD further showcases Digital China’s leadership and China’s growing influence in shaping global AI innovation.

Professor Chen Guoli remarked: “This case firmly validates Digital China’s AI transformation methodology and enriches global academic research by contributing to the theoretical framework of digital transformation and AI application—bridging Chinese practice with the global academic community.”

Thai Deputy Prime Minister and Minister of Energy Visits GoodWe

SUZHOU, China, May 30, 2025 /PRNewswire/ — In its global headquarters, GoodWe recently welcomed a high-level delegation from Thailand, led by Deputy Prime Minister and Minister of Energy Mr. Pirapan Salirathavibhaga. This visit was part of Thailand’s broader initiative to promote clean energy and deepen industrial cooperation with China. During his visit, the Deputy Prime Minister remarked that he was impressed by GoodWe’s growth over the past 15 years and expressed expectations for the company’s continued contribution to the energy sector, stating he was “looking forward to its achievements over the next 15 years.”

Meeting between Thai delegation and GoodWe
Meeting between Thai delegation and GoodWe

GoodWe’s CEO Daniel Huang and senior executives hosted the delegation and engaged in a meeting focusing on Thailand’s energy transition, clean energy trends, and long-term collaboration opportunities. Mr. Daniel expressed great appreciation to the delegation for their visit, which he described as “an important milestone for GoodWe in fostering closer ties with Thailand’s energy leadership” in his welcome remarks.

Since entering the Thai market in 2014, GoodWe has established a strong local presence through strategic partnerships with major distributors and dedicated service support based in Bangkok. Its solar inverters and energy solutions have been deployed across residential, and commercial and industrial (C&I) applications, earning trust in a wide range of high-profile solar and storage projects.

During the meeting, the Thai delegation expressed particular interest in GoodWe’s roots in the residential market and its innovations in the C&I sector. They noted that while the Thai market has focused on C&I applications, it also presents increasing potential for residential solar adoption, making GoodWe’s comprehensive solutions in this area valuable.

The visit included a tour of the GoodWe Smart Energy Showroom, where the delegation was introduced to the company’s latest innovations in photovoltaic and energy storage solutions, as well as its integrated approach to building a future-proof energy ecosystem that coordinates key components of the energy chain—power generation, grid, load, and storage—through smart control. Thai officials acknowledged the strong alignment between these innovations and Thailand’s evolving energy strategy.

“We are honored to support Thailand’s clean energy transition and remain committed to delivering high-efficiency, safe, and smart energy solutions that power a sustainable future,” said Mr. Huang, “With continuous investment in R&D across residential, C&I, and utility-scale applications, we aim to contribute to accelerate Thailand’s smart energy transition and beyond.”

So-Young Announces Plan to Implement ADS Ratio Change

BEIJING, May 30, 2025 /PRNewswire/ — So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”), the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments, today announced that the Company plans to change the ratio of the American depositary shares (“ADSs”) to its Class A ordinary shares from thirteen (13) ADSs representing ten (10) Class A ordinary shares to one (1) ADS representing fifteen (15) Class A ordinary shares.

For the Company’s ADS holders, the change in the ADS ratio will result in an effect equivalent to a proportional reverse ADS split. There will be no change to the Company’s Class A ordinary shares. The effect of the ratio change on the ADS trading price on Nasdaq is expected to take place at the open of trading on June 30, 2025 (U.S. Eastern Time). ADS holders of record on the effective date will not be required to take any action in connection with the ADS ratio change. The exchange of then-held (old) ADSs for new ADS will occur automatically with the then-held ADSs being cancelled and new ADSs being issued by the depositary bank, in each case as of the effective date for the ADS ratio change. The ADSs will continue to be traded on Nasdaq under the symbol “SY.”

No fractional new ADSs will be issued in connection with the change in the ADS ratio. Instead, fractional entitlements to new ADSs will be aggregated and sold by the depositary bank and the net cash proceeds from the sale of the fractional ADS entitlements (after deduction of fees, taxes and expenses) will be distributed to the applicable ADS holders by the depositary bank.

As a result of the change in the ADS ratio, the ADS price is expected to increase proportionally, although the Company can give no assurance that the ADS price after the change in the ADS ratio will be equal to or greater than a proportional price based on ADS price before the change.

About So-Young International Inc.

So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”) is the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments. The Company provides access to aesthetic treatments through its online platform and branded aesthetic centers, offering curated treatment information, facilitating online reservations, delivering high-quality treatments, and developing, producing and distributing optoelectronic medical equipment and injectable products. With its strong brand recognition, digital reach, affordable treatments and efficient supply chain, So-Young is well-positioned to serve its audience over the long term and grow along the medical aesthetic value chain.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Statements that are not historical facts, including but not limited to statements about So-Young’s beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law.

For more information, please contact:

So-Young

Investor Relations
Ms. Mona Qiao
Phone: +86-10-8790-2012
E-mail: ir@soyoung.com 

Christensen

In China
Ms. Yang Song
Phone: +86-10-5900-1548
E-mail: yang.song@christensencomms.com 

In US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
E-mail: linda.bergkamp@christensencomms.com

Man Confesses to Teen Murder Driven by Obsession, Case Sent to Prosecutor

An offender were arrested by the police (Photo: Ministry of Public Security of Attapeu)

Attapeu authorities brought a 40-year-old man to the scene of a crime he allegedly committed in February, where he is accused of murdering his 17-year-old sister-in-law.

OLIVE YOUNG SUMMER SALE FOR INTERNATIONAL CUSTOMERS BEGINS

SEOUL, South Korea, May 30, 2025 /PRNewswire/ — CJ Olive Young, Korea’s leading beauty and health retailer, has officially launched the OLIVE YOUNG SUMMER SALE on its international mobile app and website. Formerly known as the “Big Bang Sale,” this major promotion is now part of Olive Young’s newly rebranded seasonal campaign, held four times a year.

OLIVE YOUNG SUMMER SALE POSTER
OLIVE YOUNG SUMMER SALE POSTER

From trending K-beauty must-haves in Korea to viral social media favorites, shoppers can enjoy exclusive deals during this one-week event held each season. The OLIVE YOUNG SUMMER SALE runs from May 31 to June 6.

This summer’s sale spotlights seven “Hero Brands”, all beloved by K-beauty fans around the world (listed in alphabetical order): Anua, BIOHEAL BOH, CLIO, MEDIHEAL, ROUND LAB, Torriden, and UNOVE.

Customers in the U.S. and select regions can enjoy free shipping on orders over $60, and first-time buyers receive a 15% welcome coupon on their initial purchase. Search for “Olive Young Global” to download the app or visit the website to start shopping. With discounts of up to 77%, the event offers global customers the chance to explore the most sought-after Korean beauty products at unbeatable prices.

CJ Olive Young operates the Olive Young Global app and website, serving customers in over 150 countries with a growing community of 2.4 million members. With more than 10,000 products from Korea’s leading beauty brands, Olive Young brings the best of K-beauty to one convenient destination.

Visit https://global.oliveyoung.com/ to explore the OLIVE YOUNG SUMMER SALE lineup.

Sold out in 3 minutes! How a Sri Lankan streamer masters Chinese e-commerce live streaming?

BEIJING, May 30, 2025 /PRNewswire/ — Finding Answers in China from China.org.cn:

How did a bottle of chili paste from Sri Lanka make its way overseas and go viral in a Chinese live streaming? And how did a traditional handmade stool help revive the rural economy in Sri Lanka? What made a live streaming that sold out its inventory in just 3 minutes convince Sri Lankan entrepreneur Chiranjaya Udumullage of the huge potential and strong vitality of the Chinese market?

Devinder Kumar, a host from CICG Europe-Asia, enters the live streaming room, eager to find out how Chiranjaya Udumullage is promoting business and sale for his hometown’s quality products.

Sold out in 3 minutes! How a Sri Lankan streamer masters Chinese e-commerce live streaming
Sold out in 3 minutes! How a Sri Lankan streamer masters Chinese e-commerce live streaming

Sold out in 3 minutes! How a Sri Lankan streamer masters Chinese e-commerce live streaming?
https://youtu.be/TH78bxKCIJk

Elegoo Expands CSR Programs for Social Inclusion, Marking 10 Years of Empowering Creators

SHENZHEN, China, May 30, 2025 /PRNewswire/ — Elegoo, a rapidly developing brand in global smart manufacturing, has expanded its corporate social responsibility (CSR) programs with the launch of ELEGOO Empowers, a new initiative promoting social inclusion, STEM education, and equal opportunity through 3D printing technology. The launch marks a key milestone as the company celebrates its 10th anniversary.

Students exploring Elegoo’s Neptune series 3D printer during a workshop. Photo courtesy of Alconbury CofE Primary School.
Students exploring Elegoo’s Neptune series 3D printer during a workshop. Photo courtesy of Alconbury CofE Primary School.

This initiative builds on and unifies Elegoo’s ongoing CSR efforts under a stronger, more cohesive framework, including three key programs:

ELEGOO Gives A Hand: Harnessing 3D printing to deliver practical, reliable solutions for people and animals in need, while inspiring creativity and joy among users worldwide. From prosthetics to harnesses and assistive devices, Elegoo develops these in collaboration with partners like 3D Pets. More heartwarming projects are on the way.

ELEGOO With Her: Encouraging more women to develop their 3D printing skills through hands-on workshops and a supportive community. As the first 3D printer manufacturer to take meaningful steps toward addressing the gender gap, Elegoo is creating a more inclusive space where women can learn, connect, and build projects that expand the possibilities of 3D printing and create real-world impact. Projects by current participants will be showcased this June.

ELEGOO In Action: Promoting STEM education by providing 3D printers, supporting learning initiatives, and offering hands-on resources to schools, libraries, and student clubs worldwide, helping young creators explore robotics, model car building, and other real-world applications. Since last year, Elegoo has partnered with over 120 schools and student teams around the world.

“With ELEGOO Empowers, we’re taking that spirit beyond the desktop to help build a more inclusive and connected world,” said Chris Hong, Founder and CEO of Elegoo. “Inspired by the voices of our users, we will continue on this path and warmly invite more partners to join us in making this technology more meaningful and accessible.”

As 3D printing continues to evolve, Elegoo has spent the past 10 years leveraging the technology to empower users around the world. Many have shared their “ELEGOO moments” of giving back and helping others. Looking ahead, Elegoo is committed to making 3D printing more accessible and advancing its ESG efforts to create a more sustainable and inclusive future.

About Elegoo

Founded in 2015, Elegoo is a rapidly developing brand in the global smart manufacturing industry, specializing in R&D, manufacturing, and sales of consumer-grade 3D printers, laser engravers, STEM kits, and other smart technology products. Located in Shenzhen, the Silicon Valley of China, the company has sold millions of products across more than 90 countries and regions. In 2024, the company’s total sales revenue surpassed 200 million USD, with more than 800 employees and nearly 30,000 square meters of office and manufacturing area. With a focus on programming and 3D printing technology, Elegoo provides unique and smart creation spaces for diverse consumers to enhance personalized experiences.

GC Biopharma’s Phase 3 Clinical Trial Results for Hunterase Published in SCIE-Indexed Journal

YONGIN, South Korea, May 30, 2025 /PRNewswire/ — GC Biopharma, a South Korean pharmaceutical company, announced that the Phase 3 clinical trial results for Hunterase (idursulfase beta), its investigational drug for Hunter Syndrome (MPS II), have been published in Genetics in Medicine, an SCIE-indexed journal.

Conducted at Samsung Medical Center, the Phase 3 clinical trial enrolled 24 newly diagnosed Hunter Syndrome patients with no prior treatment. It evaluated the efficacy and safety of Hunterase over a one-year treatment period.

Hunter Syndrome is a rare genetic disorder caused by a deficiency of iduronate-2-sulfatase (IDS), an enzyme critical for glycosaminoglycan (GAG) catabolism. This deficiency leads to the progressive accumulation of GAGs in various organs and tissues, resulting in multisystemic dysfunction, including joint stiffness and hepatosplenomegaly.

The clinical trial results demonstrated that Hunterase significantly enhanced functional mobility, reduced urinary GAG concentrations, and markedly alleviated hepatosplenomegaly.

In the 6-Minute Walk Test (6-MWT), the primary endpoint of the study, patients treated with Hunterase walked an average of 62.2 meters more after treatment. This improvement was more than eight times greater compared to the placebo group, which saw an average increase of just 7.3 meters.

The 6-MWT measures the distance a patient can walk on a flat surface within 6 minutes. It is a widely used clinical measure for evaluating functional mobility, cardiopulmonary function, muscle strength, and overall physical health. In the context of Hunter syndrome, it serves as a standardized and meaningful indicator of disease progression and quality of life.

In addition to the primary endpoint, the study also achieved positive outcomes in secondary endpoints, including changes in urinary total glycosaminoglycan (GAG) levels, as well as heparan sulfate (HS) and dermatan sulfate (DS) levels. The GAG levels decreased by 71%, while HS and DS levels decreased by 89% and 88%, respectively. Moreover, liver and spleen volumes were reduced by 27% and 26%, respectively, demonstrating the drug’s effectiveness in addressing organ enlargement commonly associated with the disease.

Hunterase also demonstrated a favorable safety profile. Most adverse events were mild or moderate, and no patients discontinued treatment due to side effects. Notably, only 19% of the patients had neutralizing antibodies detected three or more consecutive times, which is significantly lower than the 62.5% observed with the existing treatments. This suggests that Hunterase may offer a more sustained therapeutic effect compared to other currently available therapy.

“This clinical trial is especially meaningful as it represents the first Phase 3 study in Asian patients to validate the clinical efficacy of Hunterase”, said Professor Young Bae Sohn of Ajou University School of Medicine and Ajou University Hospital, the journal’s first author. “The results showed significant clinical improvement not only in metabolic markers but also in organ size normalization and restoration of physical mobility.”

“We are thrilled to publish our encouraging phase 3 clinical trial results”, stated Jae Uk Jeong, Head of R&D at GC Biopharma. “Hunterase, developed in Korea using our proprietary technology, has the potential to significantly improve the lives of patients with Hunter syndrome.”

Hunter Syndrome is an X-linked lysosomal storage disorder, affecting approximately 1 in 100,000 male births. In severe cases, the patients experience early death before they reach adulthood, highlighting the need for early diagnosis and treatment. Currently, two treatments are widely available worldwide for Hunter Syndrome: GC Biopharma’s Hunterase and Takeda’s Elaprase.

About GC Biopharma

GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo™(intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit https://www.gcbiopharma.com/eng/

This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma’s management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule.

GC Biopharma Contacts (Media)

Sohee Kim
shkim20@gccorp.com

Yelin Jun
yelin@gccorp.com

Yoonjae Na
yjy6520@gccorp.com